+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-06-10Number of Pages: 101

Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022


Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.

This research report on the glioblastoma treatment market explains various advancements in this market and analyzes the global glioblastoma treatment market based on drugs (commercially available and pipeline) and geographic regions. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments dominating the market and expected to grow at the highest growth rate during the forecast period are included in the report in a precise manner.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global glioblastoma treatment market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis and Porter’s Five Forces analysis and key players’ market share analysis in 2013 in the glioblastoma treatment market. The research report also provides event impact analysis and various drug delivery methods such as nucleic acid delivery method and biomedical delivery method for the treatment of glioblastoma. 

Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. The report on glioblastoma market also provides % compound annual growth rate (CAGR) for each of the market segments mentioned above for the forecast period from 2014 to 2022, considering 2013 as the base year. 

Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II).  Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. The report on the glioblastoma treatment market also provides % compound annual growth rate (CAGR) for each of the phase III molecules individually for the forecast period from 2014 to 2022. 

Geographically, the glioblastoma treatment market has been categorized into North America, Europe, Asia-Pacific and Rest of the World. The market size and forecast for each of these regions have been provided for the period from 2012 to 2022 along with CAGR (%) for the forecast period from 2014 to 2022. 

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics.   

The pipeline review of glioblastoma treatment market has been segmented as below:
  • Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
    • Bevacizumab (Avastin)
    • Temozolomide (Temodar and Temodal and Temcad)
    • Carmustine (BiCNU)
  • Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World
  • Global Pipeline Review of Glioblastoma Treatment
    • Overview
    • Late Stage (Phase III)
      • DCVax
      • Rindopepimut (CDX-110)
      • Others
    • Early Stage (Phase I, II and Pre clinical)
      • ABT-414
      • MM-398
      • ARC-100
      • AV0113
      • Cotara
      • Crenolanib
      • SGT-53
      • Endostatin
      • ANG1005
    • Others


Chapter 1 Preface
1.1 Report Description

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022)
2.2 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million)
2.3 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Overview
     3.2.1 Subtypes of Glioblastoma Multiforme
             3.2.1.1 Signatures and Clinical features of GBM subtypes
     3.2.2 Epidemiology
     3.2.3 Standard treatment options and alternative therapeutics approaches
3.3 Nucleic Acid Delivery Methods
     3.3.1 Virus-based
     3.3.2 Nonviral-based
     3.3.3 Stem cells
3.4 In Vivo Identification of GBM for Diagnostic Implication
     3.4.1 Magnetic Resonance Imaging (MRI)
     3.4.2 Computed Tomography (CT)
     3.4.3 Positron Emission Tomography (PET)
     3.4.4 Others
3.5 Biomolecule delivery systems
     3.5.1 For Glioblastoma
             3.5.1.1 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma
     3.5.2 For other Central Nervous System (CNS) disorders
3.6 Market Dynamics
     3.6.1 Drivers
             3.6.1.1 Rising geriatric population will drive the GBM treatment market as they are more prone to cause GBM
             3.6.1.2 Global Rate of Aging Population
             3.6.1.3 Various government and non-government organizations are creating worldwide awareness against GBM
             3.6.1.4 The future of glioblastoma treatment market expects introduction of several novel therapies due to its strong pipeline
     3.6.2 Restraints
             3.6.2.1 GBM is highly resistant to DNA modifying agents hence available therapies have limitations
             3.6.2.2 The overall survival period delivered by current FDA approved treatments is less
     3.6.3 Opportunities
             3.6.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments
3.7 Event Impact Analysis
3.8 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million)
     3.8.1 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million)
     3.8.2 Bevacizumab (Avastin)
             3.8.2.1 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million)
     3.8.3 Temozolomide
             3.8.3.1 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million)
     3.8.4 Carmustine (BiCNU)
             3.8.4.1 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million)
3.9 Global Glioblastoma Treatment Market Revenue and Forecast, by Geography, 2012 – 2022 (USD Million)
     3.9.1 North America
             3.9.1.1 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
     3.9.2 Europe
             3.9.2.1 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
     3.9.3 Asia Pacific
             3.9.3.1 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
     3.9.4 Rest of the World (RoW)
             3.9.4.1 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
3.10 Competitive Landscape
     3.10.1 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)

Chapter 4 Global Pipeline Review of Glioblastoma Treatment
4.1 Overview
4.2 Pipeline Analysis : Types of Therapies
     4.2.1 Targeted Therapy
             4.2.1.1 TRC-105
     4.2.2 Gene Therapy
             4.2.2.1 VB-111
             4.2.2.2 TOCA 511
     4.2.3 Immunotherapy
             4.2.3.1 DCVax-Brain
             4.2.3.2 Rindopepimut (CDX-110)
             4.2.3.3 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut
             4.2.3.4 ICT-107
             4.2.3.5 Trivax (AV00113)
4.3 Phase I and II Drug Entities

Chapter 5 Recommendations
5.1 Market Strategy for Success
     5.1.1 Focus on the development of immunotherapy and biological therapy treatments
     5.1.2 Development of novel drug delivery system (NDDS)
     5.1.3 Expected intense competition in the near future

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
     6.1.1 Company Overview
     6.1.2 Financial Overview
     6.1.3 Product Portfolio
     6.1.4 Business Strategies
             6.1.4.1 Acquisitions and partnership for market penetration
     6.1.5 Recent Developments
6.2 Activartis GmbH
     6.2.1 Company Overview
     6.2.2 Financial Overview
Being a privately owned company, the financial results of Activartis Biotech GmbH is not available in the public domain.
     6.2.3 Product Portfolio
     6.2.4 Business Strategies
             6.2.4.1 Strong focus on research and development
     6.2.5 Recent Developments
6.3 Agenus Inc.
     6.3.1 Company Overview
     6.3.2 Financial Overview
     6.3.3 Product Portfolio
     6.3.4 Business Strategies
             6.3.4.1 Acquisition & Merger
     6.3.5 Recent Developments
6.4 Arog Pharmaceuticals, Inc.
     6.4.1 Company Overview
     6.4.2 Financial Overview
     6.4.3 Product Portfolio
     6.4.4 Business Strategies
             6.4.4.1 Research and development
     6.4.5 Acquisition of worldwide rights
     6.4.6 Recent Developments
6.5 Bristol-Myers Squibb Company
     6.5.1 Company Overview
     6.5.2 Financial Overview
     6.5.3 Product Portfolio
     6.5.4 Business Strategies
             6.5.4.1 Acquisitions for company’s growth
     6.5.5 Recent Developments
6.6 Cavion LLC
     6.6.1 Company Overview
     6.6.2 Financial Overview
     6.6.3 Product Portfolio
     6.6.4 Business Strategies
             6.6.4.1 New Drug Development
6.7 Celldex Therapeutics Inc.
     6.7.1 Company Overview
     6.7.2 Financial Overview
     6.7.3 Product Portfolio
     6.7.4 Business Strategies
             6.7.4.1 Strong Pipeline portfolio
     6.7.5 Recent Developments
6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
     6.8.1 Company Overview
     6.8.2 Financial Overview
     6.8.3 Product Portfolio
     6.8.4 Business Strategies
             6.8.4.1 Strong Pipeline portfolio
     6.8.5 Recent Developments
6.9 Cortice Biosciences Inc.
     6.9.1 Company Overview
     6.9.2 Financial Overview
     6.9.3 Product Portfolio
     6.9.4 Business Strategies
            6.9.4.1 Acquisition of Exclusive Commercial Rights
     6.9.5 Recent Developments
6.10 Eisai Co., Ltd.
     6.10.1 Company Overview
     6.10.2 Financial Overview
     6.10.3 Product Portfolio
     6.10.4 Business Strategies
              6.10.4.1 Joint Research Agreement
              6.10.4.2 Introduction of new lifestyle information website for breast cancer patients
     6.10.5 Recent Developments
6.11 Exelixis Inc.
     6.11.1 Company Overview
     6.11.2 Financial Overview
     6.11.3 Product Portfolio
     6.11.4 Business Strategies
              6.11.4.1 Strong Pipeline portfolio
              6.11.4.2 Partnered compounds
     6.11.5 Recent Developments
6.12 F. Hoffmann-La Roche Ltd.
     6.12.1 Company Overview
     6.12.2 Financial Overview
     6.12.3 Product Portfolio
     6.12.4 Business Strategies
              6.12.4.1 Investment in research and development (R&D)
              6.12.4.2 Strengthening core business
              6.12.4.3 Mergers and Acquisitions
     6.12.5 Recent Developments
6.13 Peregrine Pharmaceuticals, Inc.
     6.13.1 Company Overview
     6.13.2 Financial Overview
     6.13.3 Product Portfolio
     6.13.4 Business Strategies
              6.13.4.1 Licensing agreements and collaborations
              6.13.4.2 Research and development approach
     6.13.5 Recent Developments
6.14 OncoSynergy
     6.14.1 Company Overview
     6.14.2 Financial Overview
     6.14.3 Product Portfolio
     6.14.4 Business Strategies
     6.14.5 Recent Developments
6.15 Merrimack Pharmaceuticals, Inc.
     6.15.1 Company Overview
     6.15.2 Financial Overview
     6.15.3 Product Portfolio
     6.15.4 Business Strategies
              6.15.4.1 Acquisition and collaboration agreement to gain market share
     6.15.5 Recent Developments

List of Figures

FIG. 1 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million)
FIG. 2 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)
FIG. 3 Median Overall Survival Time of Glioblastoma Patients, by Therapy
FIG. 4 Global Rate of Aging Population
FIG. 5 Global Glioblastoma Treatment Market: Event Impact Analysis
FIG. 6 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million)
FIG. 7 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million)
FIG. 8 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million)
FIG. 9 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
FIG. 10 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
FIG. 11 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
FIG. 12 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
FIG. 13 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)
FIG. 14 Pipeline Analysis: Glioblastoma Treatment
FIG. 15 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 16 Agenus Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 17 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 18 Eisai Co., Ltd.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 19 Exelxis Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 20 F. Hoffmann-La Roche Ltd: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Peregrine Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022) 15
TABLE 2 Signatures and Clinical features of GBM subtypes 21
TABLE 3 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma 32
TABLE 4 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million) 40
TABLE 5 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut 58


Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). In case of GBM treatment, there are many restraints and challenges such as its resistance against DNA-modifying agents, migration of malignant cells into adjacent brain tissues increases the complexity of the surgery, and current FDA approved treatments may cause neurotoxicity in patients. Thus, as available treatment options lack in efficiency, the mortality rate of glioblastoma is characterized by rapid progression and poor survival rate with only 8.7% of the patients surviving more than two years post diagnosis. According to Centers for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumors of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence.

Although, the rising mortality rate of GBM has made it one of the lethal type of cancers; the pipeline of GBM is well equipped with various types of novel therapies including immunotherapy, biologics, small molecules and other drugs. The pipeline of GBM is currently rich in number of various therapeutic drugs and devices that are expected to receive FDA approvals for conducting the clinical trials. The FDA approved drugs currently present in market are temozolomide (Temodar, Temodal and Temcad), bevacizumab (Avastin) and carmustine wafers (BiCNU). The geographical segmentation of GBM market comprises North America, Europe, Asia Pacific and Rest of the World. Bevacizumab (Avastin) is the latest addition to this artillery, while temozolomide was leading the GBM market in 2013 due to it’s effectiveness when combined with surgery. Bevacizumab is the first monoclonal antibody drug approved for GBM treatment which is more efficient than temozolomide and is expected to surpass its revenue by 2016. Temozolomide market was drastically affected in 2013 as it has lost the market exclusivity in 2012 and generics manufactured by Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market. Geographically, in 2013 North America was observed as the most leading GBM market due to increasing support from government and non-government organizations to raise public awareness by and advanced healthcare infrastructure to boost the pipeline research in this market. Asia Pacific is the fastest growing market, rising awareness against GBM is boosting the diagnostic rate in this region and developing healthcare infrastructure is also assisting the market growth.

The pipeline analysis of GBM treatment include biologics, small molecules, devices, surgeries, and immunotherapy. In the current scenario, the pipeline review of glioblastoma seems to be strong as more than 50 molecules are in phase I and phase II clinical trials. The most promising drugs in phase III trials are Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These molecules have performed well in phase II of the clinical trials in terms of exceeding the overall survival rate. 

The key players involved in the GBM market are Abbvie, Inc., Celldex Therapeutics, Inc., Exellixis, Inc., Brostol-Myers Squibb Co. and F. Hoffman La Roche. In 2013, F. Hoffman La Roche was observed to be the most promising and efficient source of GBM treatment due to its novel drug delivery system known as “brain shuttle.

pipeline-review-of-glioblastoma-treatment-market


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries